scispace - formally typeset
Journal ArticleDOI

Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

Reads0
Chats0
TLDR
6β-OHF urinary excretion is a good test to evaluate drug-metabolising enzyme inducing or inhibiting properties of drugs when the subjects are their own controls, but this test is not reliable enough to measure actual CYP3A4 activity.
Abstract
6β-Hydroxycortisol (6β-OHF) urinary excretion has, for a long time, been considered a marker of drug induction and, more recently, of drug inhibition in humans and in laboratory animals, but its specificity is still under debate. In this work, we review 277 papers devoted to 6β-OHF urinary excretion. We have evaluated factors that could modify 6β-OHF excretion and, thus, could explain contradictory results. We have examined the effect of the analytical techniques on physiological values. Intra- and inter-individual variability and the effect of circadian rhythms on urinary excretion of 6β-OHF as well as cortisol and 17-hydroxycorticosteroids have been evaluated. We also give an overview of drugs that induce, inhibit or have no effect on 6β-OHF. For inducing and inhibiting drugs, we calculated the ranges of variation of 6β-OHF excretion from the results indicated in the different papers. This work was done for well-known inducers, such as anticonvulsants, but also for other inducing or inhibiting drugs found in the literature. The time-course of variation in 6β-OHF excretion when different drugs are co-administered was also investigated. The potential relationship between cytochrome P 450 3A4 (CYP3A4) polymorphism and 6β-OHF excretion was studied. Finally, the interest of 6β-OHF urinary excretion was compared with that of other tests proposed to measure CYP3A4 activity. This review demonstrates that 6β-OHF urinary excretion is a good test to evaluate drug-metabolising enzyme inducing or inhibiting properties of drugs when the subjects are their own controls, but this test is not reliable enough to measure actual CYP3A4 activity.

read more

Citations
More filters
Journal ArticleDOI

Inhibition and induction of human cytochrome P450 enzymes: current status.

TL;DR: This review covers both inhibition and induction of CYP enzymes, always keeping in mind the basic mechanisms on which to build predictive and preventive in vitro approaches.
Journal ArticleDOI

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.

TL;DR: Phenotyping for drug metabolizing enzymes and transporters is used to assess quantitatively the effect of an intervention or a condition on their activity to obtain results applicable for other substrates of the respective enzyme/transporter.
Journal ArticleDOI

Drugs as CYP3A probes, inducers, and inhibitors.

TL;DR: This review systematically summarized the frequently used CYP3A probe drugs, inducers and inhibitors, and evaluated their current status in drug development and research.
Journal ArticleDOI

Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem.

TL;DR: CYP3A4 pharmacogenetics/genomics from the early inheritance estimations up to the most recent genetic and clinical studies are summarized, including new findings about SNPs in CYP3A 4 and other genes (P450 oxidoreductase (POR), peroxisome proliferator-activated receptor alpha (PPARA)) with possible contribution to CYP 3A4 variable expression are summarized.
Journal ArticleDOI

4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

TL;DR: The concentration of 4β-OHC was higher in women than in men, confirming previous studies indicating a gender difference in CYP3A4/5-activity, and is a sensitive marker of CYP 3A activity, especially to assess induction but also inhibition.
References
More filters
Journal Article

Pharmacological implications of microsomal enzyme induction

TL;DR: It is of considerable interest that certain inducers of liver microsomal enzymes have recently been used therapeutically for the treatment of hyperbilirubinemia in jaundiced children and for thetreatment of Cushing's syndrome.
Journal ArticleDOI

CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism

TL;DR: Several issues remain to be resolved regarding the catalytic activity of the P-450 3A4 protein, including rate-limiting steps and the need for cytochrome b5, divalent cations, and acidic phospholipid systems for optimal activity.
Journal ArticleDOI

In vitro and in vivo drug interactions involving human cyp3a

TL;DR: Cytochrome P4503A (CYP3A) is importantly involved in the metabolism of many chemically diverse drugs administered to humans and makes it a major contributor to presystemic elimination following oral drug administration.
Journal ArticleDOI

Cytochrome P450 3A: ontogeny and drug disposition.

TL;DR: Investigators and clinicians should consider the impact of ontogeny on CYP3A in both pharmacokinetic study design and data interpretation, as well as when prescribing drugs to children, because of the potential impact on the clinical pharmacokinetics of these drugs.
Related Papers (5)